Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

NCT07023835 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Interventions

DRUG: 50 mg Usnoflast
DRUG: 75 mg Usnoflast
DRUG: Placebo

Sponsor

Zydus Therapeutics Inc.